We bring Science to you. We create powerful therapeutic solutions through our strong commitment to R&D within key areas, focusing our innovation at every point in the pharmaceutical value chain. A consolidated profitable growth gives us the opportunity to devote our talent and efforts towards specialty areas and particularly in helping to treat all major skin diseases through our advances in dermatology.
Our therapeutic focus.
Actinic keratosis develops as a result of chronic UV damage in skin areas that are constantly exposed to sunlight. This condition is also commonly known as solar keratosis, senile keratosis & age keratosis. Due to many years of repeated sun damage, the genetic information in the cells of the uppermost skin layer (keratinocytes) changes so that they are reformed more quickly.
The probability of developing actinic keratosis is greatest in old age and amongst fair-skinned people. It is estimated that around half of all Europeans over 60 are affected. Today, it is known that actinic keratosis is an early form of non-melanoma skin cancer. In contrast to other forms of skin cancer, however, actinic keratosis is not malignant, as it only affects the top-most skin layer.
Eczema is a form of skin inflammation with various pathogenic origins. The various subtypes of eczema are differentiated by the underlying cause of skin inflammation, such as atopic eczema, toxic contact eczema or allergic contact eczema.